AbbVie ( ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for its ...

Novo Nordisk downgraded to Buy amid guidance cuts & competition. Explore its long-term obesity drug potential, strong ...

Denmark’s status as one of the few countries in Europe with an expanding economy rests in part on the success of its homegrown hero, Novo Nordisk A/S. Thanks to the pharmaceutical giant’s astronomical ...

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting ...